ACE inhibitor-vasopressin antagonist combinations
Combinations of ACE inhibitors and vasopressin antagonists are useful to slow and reverse the process of ventricular dilation, and CHF in mammals.
1 . A pharmaceutical composition comprising an effective amount of an angiotensin-converting enzyme inhibitor and an effective amount of a vasopressin antagonist.
2 . A composition according to claim 1 employing an ACE inhibitor selected from captopril, enalapril, enalaprilat, lisinopril, ramipril, zofenopril, trandolapril, temocapril, ceranapril, alacepril, delapril, pentopril, quinapril, quinaprilat, moexipril, rentiapril, duinapril, spirapril, cilazapril, perindopril, and fosinopril.
3 . A composition according to claim 1 employing a vasopressin antagonist of Formula I
wherein R and R 5 are hydrogen or lower alkyl;
R 1 , R 2 , and R 3 independently are hydrogen, halo, lower alkyl, lower alkoxy, amino, alkylamino, or dialkylamino; and
R 4 is hydrogen, phenyl or substituted phenyl, and pharmaceutically acceptable salts thereof.
4 . A composition according to claim 3 in which the vasopressin antagonist is conivaptan.
5 . A composition according to claim 2 comprising an ACE inhibitor selected from quinapril hydrochloride, ramipril, enalapril, or moexipril.
6 . A composition according to claim 5 comprising a vasopressin antagonist selected from conivaptan or a salt thereof.
7 . A composition comprising conivaptan and quinapril.
8 . A method for treating ventricular dilation, and/or heart failure in a mammal comprising administering an effective amount of a combination of at least one angiotensin-converting enzyme inhibitor and at least one vasopressin antagonist.